A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.
Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.
More top news
Father of Paul Walker says the car 'lacked safety features' that would have saved his life
Investigating judge in Belgium charges man with murder and participation in the activities of a terrorist organisation: reports
Margaret Rigby spent £57,000 of her friend's money on luxury goods for herself, after gaining power of attorney